NCT04811651View on ClinicalTrials.gov

Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2024

Conditions
Ischemic Stroke
Interventions
BIOLOGICAL

Umbilical Cord-derived Mesenchymal Stem Cells

umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.

DRUG

Placebo

intravenous placebo solution with the same appearance as the treatment group.

Trial Locations (1)

110016

Department of Neurology, General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors
lead

General Hospital of Shenyang Military Region

OTHER

NCT04811651 - Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke | Biotech Hunter | Biotech Hunter